Audentes Therapeutics’ “Be Bold for Courageous Patients” Program to Support Patients Living with Rare Diseases
In recognition of Rare Disease Day, Audentes Therapeutics announces their new “Be Bold for Courageous Patients” program.
Sanofi Genzyme Announces Recipients of 2016 Patient Advocacy Leadership (PAL) Awards
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the recipients of the sixth annual Patient Advocacy Leadership (PAL) Awards. The global PAL Awards program supports projects by non-profit organizations that serve patients living with lysosomal storage disorders (LSDs), a group of rare, inherited disorders that can cause progressive and debilitating health problems.
Sanofi Genzyme Announces Recipients of Patient Advocacy Leadership (PAL) Awards
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the recipients of the fifth annual Patient Advocacy Leadership (PAL) awards. The global grant program supports projects by non-profit organizations that serve patients living with lysosomal storage disorders (LSDs), a group of rare, inherited disorders that can cause progressive and debilitating health problems.
Audentes Therapeutics Joins Global Organizations In Celebrating Rare Disease Day® 2015
SAN FRANCISCO, CA – February 26, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced its support for Rare Disease Day®, to be held on February 28th, 2015. The theme of this year’s Rare Disease Day is Living with a Rare Disease. In honor of the day, Audentes is pleased to announce the launch of a website.
Genzyme Recognizes International Rare Disease Day with Global Awareness Programs and Launch of Fourth Annual Patient Advocacy Leadership (PAL) Awards
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced its support of International Rare Disease Day with a series of initiatives meant to call attention to rare diseases as an important public health issue and to improve rare disease education, research, and treatment.
Genzyme Recognizes International Rare Disease Day with Second Annual Patient Advocacy Grant Program
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced its support of International Rare Disease Day with a series of events to celebrate and recognize the global rare disease community.
Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program
Genzyme Corporation (NASDAQ: GENZ) today recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards (PAL Awards).
MP Dr. Kirsty Duncan’s letter to the Speaker of the House of Commons on February 28 (Rare Disease Day)
Mr. Speaker, some 2.7 million Canadians are affected by 1 in 6,000 rare disorders, such as cystic fibrosis, sickle cell disease and thalassemia. Most rare disorders are difficult to diagnose and are chronic, degenerative, progressive and life-threatening.